Bank of America Corp DE Purchases 349,732 Shares of Tyra Biosciences, Inc. $TYRA

Key Points

• Bank of America purchased 349,732 Tyra Biosciences shares worth approximately $11.17 million, taking a 0.59% stake. Institutional investors and hedge funds collectively own 84.14% of the company.
• Tyra shares opened at $21.76, well below their 50-day and 200-day moving averages of $26.80 and $31.18, respectively. The company reported a quarterly loss of $0.69 per share, missing estimates by $0.04.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and average price target of $46.89, despite target-price reductions and the company’s expected full-year loss of $2.68 per share.

Bank of America Corp DE purchased a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 349,732 shares of the company's stock, valued at approximately $11,170,000. Bank of America Corp DE owned 0.59% of Tyra Biosciences at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Hilton Head Capital Partners LLC acquired a new stake in Tyra Biosciences in the first quarter worth $30,000. State of Wyoming acquired a new position in shares of Tyra Biosciences in the second quarter valued at approximately $76,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Tyra Biosciences during the fourth quarter worth $79,000. Canada Pension Plan Investment Board bought a new stake in shares of Tyra Biosciences during the second quarter worth $230,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Tyra Biosciences during the first quarter worth $276,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Stock Down 2.9%

NASDAQ TYRA opened at $21.76 on Friday. The firm has a market cap of $1.30 billion, a P/E ratio of -9.07 and a beta of 0.73. The company's 50 day moving average is $26.80 and its 200-day moving average is $31.18. Tyra Biosciences, Inc. has a 12-month low of $12.58 and a 12-month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Equities analysts expect that Tyra Biosciences, Inc. will post -2.68 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on TYRA shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tyra Biosciences in a research report on Friday, July 17th. Oppenheimer reaffirmed an "outperform" rating and set a $40.00 target price (down from $50.00) on shares of Tyra Biosciences in a research report on Tuesday. Jefferies Financial Group reiterated a "buy" rating and issued a $42.00 price target on shares of Tyra Biosciences in a research report on Wednesday, August 5th. Wedbush restated an "outperform" rating and set a $53.00 price objective on shares of Tyra Biosciences in a research report on Thursday, September 10th. Finally, JonesTrading began coverage on Tyra Biosciences in a research note on Wednesday, June 17th. They issued a "buy" rating and a $56.00 price objective on the stock. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $46.89.

Tyra Biosciences News Summary

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: Analysts have a consensus price target of $46.89 for Tyra Biosciences (TYRA), indicating substantial upside if the company meets expectations. Tyra Biosciences, Inc. Stock Has Consensus Price Target of $46.89
• Positive Sentiment: HC Wainwright raised its EPS forecasts across 2026 and 2027, including FY2026 losses of $2.60 per share versus a prior estimate of $2.86 and FY2027 losses of $2.27 versus $3.20 previously. The firm maintained a Buy rating and a $29 price target. The revised estimates imply expectations for narrower losses, although the company remains unprofitable.
• Neutral Sentiment: Reported short interest was listed at zero shares as of September 24, producing a 0.0-day short-interest ratio. This unusual figure provides little evidence of meaningful short-selling pressure and may reflect a reporting or data issue.
• Negative Sentiment: Tyra Biosciences shares declined after an analyst downgrade, adding immediate selling pressure and offsetting the more constructive HC Wainwright forecasts. The downgrade’s specific firm, rating change, and rationale were not provided in the available report. Tyra Biosciences Shares Down After Analyst Downgrade

Tyra Biosciences Profile

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for diseases with limited treatment options. The company uses its proprietary SNÅP platform to design small-molecule therapies intended to selectively target disease-driving genetic alterations while addressing resistance mechanisms that can reduce the effectiveness of existing treatments.

Tyra's lead programs are directed at fibroblast growth factor receptor (FGFR) biology. TYRA-300 is an oral, selective FGFR3 inhibitor being developed for conditions including FGFR3-altered urothelial cancer and achondroplasia, a genetic skeletal disorder.

Want to see what other hedge funds are holding TYRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.